english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

New special section: "Mediator° - the criminal trial"

09 October 2019

  The 2019 "Prescrire Prize" is awarded in Paris to
  3 noteworthy books about health and healthcare

The recipients of the 2019 "Prescrire Prize" book awards were announced on 3 October 2019. The prize is awarded to works of particular interest to the general public and/or healthcare professionals.
03 October 2019

Axicabtagene ciloleucel (Yescarta°) in certain types of lymphoma when other treatment options have been exhausted

FEATURED REVIEW Axicabtagene ciloleucel  is a CAR (chimeric antigen receptor) T-cell therapy. It increases the chances of survival in certain situations but frequently provokes serious adverse effects. There is a pressing need for more thorough clinical evaluation.
Full review (3 pages) available for download by subscribers.
1 October 2019

In the October issue of Prescrire International: clear shortcomings in the independence of French medical schools

FREE DOWNLOADInvestigation by a nonprofit organisation revealed poor application of a charter signed by deans of French medical and dental schools.
Full text available for free download.
1 October 2019

"Faces of Mediator", a new book published by Prescrire

Les Visages du Mediator It was after seeing the French film "La Fille de Brest", an adaptation of the book by pulmonologist and whistle-blower Irène Frachon, that the photographer Marc Dantan first got the idea of taking portraits of the victims of Mediator° (benfluorex), in the hope that "bringing faces into the light could perhaps raise awareness of the silent suffering". That was the beginning of this book, which presents in 208 pages some 180 photographs, along with a foreword by Irène Frachon, a summary of the history of the Mediator° disaster, and an afterword by Prescrire. Texts in French and English.
1 October 2019

Paracetamol: patients need to be more aware of the harms

In France, 20% of patients seem to be unaware that paracetamol is toxic at high doses, especially to the liver, and around 30% are unaware that alcohol aggravates this toxicity.
1 October 2019

Secondary cardiovascular prevention: dubious benefits of evolocumab (Repatha°) and alirocumab (Praluent°)

In patients who have already had a cardiovascular event, the addition of evolocumab or alirocumab to a statin does not reduce mortality but does expose to adverse effects, although these are not well known.
1 October 2019

Trials funded by drug companies: publication or publicity?

Pharmaceutical companies have a tight grip on the publication of the clinical study results that will allow them to obtain marketing authorisation for their products. A situation that is regrettable, but predictable.
1 October 2019

Erenumab (Aimovig°) for the prevention of migraine attacks: decrease in the frequency of attacks in some patients, but uncertainty over cardiovascular effects

FEATURED REVIEW Erenumab (Aimovig°) is a monoclonal antibody that has been authorised in the European Union for the prevention of migraine attacks in patients who experience attacks on more than 4 days a month. Prescrire's editorial staff have weighed the available evidence to bring you an unbiased assessment of the drug's harm-benefit balance.
Full review (5 pages) available for download by subscribers.
1 September 2019

In the September edition of Prescrire International: sartan medicines contaminated by impurities which are probable carcinogens

FREE DOWNLOAD The exposure of patients all around the world and over a period of several years to impurities which are known to be carcinogenic, and which were present in commonly used medicines, shows that the systems intended to guarantee pharmaceutical quality need to be improved.
Full text available for free download.
1 September 2019

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90